Sono-Tek falls 12.8% after quarterly EPS miss

What happened

Sono-Tek (SOTK) fell 12.8% on October 14, 2026, after quarterly earnings per share missed expectations tied to the company’s reported results. The company posted earnings per share of $0.02 against $0.04 expected, a shortfall of 50.0% reported by Zacks Investment Research. Management, speaking on the call, highlighted stronger medical market sales and larger orders, according to GlobeNewsWire and Zacks Investment Research. Trading opened 18.8% below the previous close and volume ran 2.6 times its 20-day average as investors reacted to the report.

How big was the move

The stock’s decline was 3.0 times a typical daily move for this stock and was 11.0 percentage points worse than the Industrials sector median, which fell 1.8% that day. The S&P 500 fell 1.1% on the session. The stock’s beta of 0.30 indicates it typically moves less than the market. Over the last five sessions the stock fell 8.0% while the S&P 500 fell 1.1% over the same span.

The technical picture

The stock remained above key moving averages even after the drop: it was 7.1% above its 20-day moving average, 16.2% above its 50-day moving average and 29.3% above its 200-day moving average. The 50-day average was above the 200-day average, a sign of an established uptrend. The stock had spent 19 consecutive trading days above the 200-day average prior to this session. Momentum indicators were neutral, with a Relative Strength Index (14 days) of 56, and the shares sat 17.0% below the 52-week high. Recent volatility was elevated, with 67% annualized volatility over 60 days, higher than 80% of its own readings over five years.

Fundamentals and valuation

For the four quarters through August 31, 2026, revenue totaled $21.5 million, which grew 4.4% from a year earlier, and diluted earnings per share were $0.11, up 11.6% year over year. Gross margin expanded to 52.5% from 48.6% a year earlier, and operating margin improved to 10.2% from 6.7% in the prior year. The company reported a free-cash-flow margin of 33.6% and return on invested capital of 8.4%. On the balance sheet the company held net cash of $10.25 billion, and share count over one year increased by 0.5%.

Valuation metrics showed a price to trailing earnings of 58.0 times trailing earnings and a price to forward earnings of 59.1 times expected earnings. The stock’s price to trailing earnings was higher than 62% of its own readings over the past five years, where the five-year median was 52.4 times earnings. Its free-cash-flow yield was 6.5%.

Earnings and analyst expectations

Sono-Tek’s October 14, 2026, report showed quarterly earnings per share of $0.02 versus $0.04 expected, a shortfall of 50.0% reported by Zacks Investment Research. The company had not beaten estimates in consecutive quarters, with an average surprise over the last four reports of 8.3% below estimates. Management’s prepared remarks, as reported by GlobeNewsWire, said first-half revenue was $10.9 Million and gross margin expanded to 55% in the fiscal second quarter. Management also flagged a 289% increase in medical market sales and stronger demand for higher-value production systems. They said recent large orders had improved visibility into fiscal 2028 and reiterated guidance of flat to modest revenue growth for fiscal 2027.

Analysts had set a consensus price target of $8.50, which was 36.9% above the closing price on the session. Typical two-day reactions after recent reports averaged a fall of 3.2%, making this session’s 12.8% decline a larger-than-usual response tied directly to the earnings miss.

What to watch

• January 12, 2027: next scheduled earnings report date.
• Management guidance: company reiterated guidance of flat to modest revenue growth for fiscal 2027, as noted in the fiscal Q2 release reported by GlobeNewsWire and MarketBeat.
• Order pipeline: management said recent large orders have improved visibility into fiscal 2028, a point emphasized on the October 14 call reported by Seeking Alpha.
• Medical market sales: the company reported a 289% increase in medical market sales in the first half, a key revenue driver cited by management.
• Analyst consensus: the $8.50 consensus price target remained 36.9% above the session close.